Myocardial fibrosis plays a key role in the pathological remodeling of the diseased heart. Yet, there is currently no routine screening method for it. The gold standard, histological examination, is highly invasive. Other alternatives are either costly (e.g. PET-CT, MRI) or subjective (echocardiography). Using HRMAS MRS, we analyzed blood samples from subjects diagnosed with common myocardial fibrosis (MF), amyloidosis (CA), or sarcoidosis (CS), plus controls. The identified regions of interest (ROI) and principal components (PC) enabled us to distinguish between diseased and not-diseased, and between the different disease groups. This may contribute to earlier diagnosis and increased success of treatment.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: